Concept
Médicament orphelin
Publications associées (54)
Inhibiting Mycobacterium tuberculosis within and without
Tuberculosis remains a scourge of global health with shrinking treatment options due to the spread of drug-resistant strains of Mycobacterium tuberculosis. Intensive efforts have been made in the past 15 years to find leads for drug development so that bet ...
Royal Soc2016Chiral gamma-Lactams by Enantioselective Palladium(0)-Catalyzed Cyclopropane Functionalizations
Cyclopropanes fused to pyrrolidines are important structural features found in a number of marketed drugs and development candidates. Typically, their synthesis involves the cyclopropanation of a dihydropyrrole precursor. Reported herein is a complementary ...
Wiley-V C H Verlag Gmbh2015The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-beta peptides
Patrick Fraering, Jianhua Liu, Jing Yu
Known gamma-secretase inhibitors or modulators display an undesirable pharmacokinetic profile and toxicity and have therefore not been successful in clinical trials for Alzheimer's disease (AD). So far, no compounds from natural products have been identifi ...
Nature Publishing Group2015Lansoprazole is an antituberculous prodrug targeting cytochrome bc1
Stewart Cole, Florence Pojer, Claudia Sala, Andrej Benjak, Anthony Vocat, Philippe Busso, Jan Lars Rybniker
Better antibiotics capable of killing multi-drug-resistant Mycobacterium tuberculosis are urgently needed. Despite extensive drug discovery efforts, only a few promising candidates are on the horizon and alternative screening protocols are required. Here, ...
Nature Publishing Group2015Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer
Paul Joseph Dyson, Tina Riedel, Gianni Sava
Aim of the study The tumor metastases targeting ruthenium complex NAMI-A synergistically improves the activity of gemcitabine in combination therapies. High-throughput screening was used to identify other potential drug combinations from a library of FDA a ...
Springer2015Automated multi-parameter measurement of cardiomyocytes dynamics with digital holographic microscopy
Gerardo Turcatti, Benjamin Rappaz, Pierre Marquet
Compounds tested during drug development may have adverse effects on the heart; therefore all new chemical entities have to undergo extensive preclinical assessment for cardiac liability. Conventional intensity-based imaging techniques are not robust enoug ...
Optical Society of America2015Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease
Hilal Lashuel, Patrick Fraering, Saviana Di Giovanni, Simona Eleuteri
Aβ accumulation plays a central role in the pathogenesis of Alzheimer's disease (AD). Recent studies suggest that the process of Aβ nucleated polymerization is essential for Aβ fibril formation, pathology spreading and toxicity. Therefore, targeting this p ...
2015Improving Risk Regulation
Marie-Valentine Renée Agnès Florin
Confronted with the challenge of improving regulatory performance, many governments in the world are looking for ways to better manage risks, in particular those risks that develop in complex systems, with stakeholders from various sectors, and that are ma ...
International Risk Governance Council (IRGC)2015A method to identify and validate mitochondrial modulators using mammalian cells and the worm C-elegans
Johan Auwerx, Laurent Mouchiroud, Pénélope Andreux, Richardus Houtkooper, Xu Wang, Norman Lionel Moullan, Adrienne Joëlle Laurence Mottis, Virginija Jovaisaite, Sabrina Bichet
Mitochondria are semi-autonomous organelles regulated by a complex network of proteins that are vital for many cellular functions. Because mitochondrial modulators can impact many aspects of cellular homeostasis, their identification and validation has pro ...
Nature Publishing Group2014Who will develop new antibacterial agents?
The golden age of antimicrobial drug development is a distant memory, and the likelihood of there being another seems slim. In part, this is because the pharmaceutical industry, which has now adopted an unsustainable business model, abandoned the anti-infe ...
Royal Soc2014